Embryo/Fetal Doses from SPECT Radiopharmaceuticals

Creative Commons License

İpek Işikci N., DEMİR M.

Turk Onkoloji Dergisi, vol.37, no.3, pp.346-350, 2022 (ESCI, Scopus, TRDizin) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 37 Issue: 3
  • Publication Date: 2022
  • Doi Number: 10.5505/tjo.2022.3385
  • Journal Name: Turk Onkoloji Dergisi
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, CINAHL, EMBASE, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.346-350
  • Keywords: Embryo/fetal dose, fetus dose, International Commission on Radiological Protection 84, SPECT radiopharmaceuticals, Tc-99m radiopharmaceuticals, FETUS, EXPOSURE
  • Open Archive Collection: AVESIS Open Access Collection
  • Istanbul University-Cerrahpasa Affiliated: No

Abstract

© 2022, Turkish Society for Radiation Oncology.OBJECTIVE The aim of this study is to calculate embryo/fetal doses in pregnant women who received99mTc-labeled radiopharmaceuticals for SPECT/CT scan. METHODS Embryo/fetal doses were estimated for 74 pregnant women underwent SPECT/CT scan from different regions of Turkey. OLINDA/EXM package program was used for radiation dose calculation from internal emitters, while CT dose was calculated from modified soft-tissue CT dose index. RESULTS The highest embryo/fetal dose was found in99mTc-methoxy isobutyl isonitrile (MIBI) myocardial perfusion scintigraphy (MPS) as (8.88+5.55=14.43 mGy) from both distinct modes (stress and rest imaging). The embryo/fetal dose from MPS slightly increased to 15.63 mGy with the CT dose contribution. Whereas,99mTc-dimercaptosuccinic acid (DMSA) static renal scintigraphy recorded the lowest embryo/ fetal dose among the other diagnostic procedures (mean 1.06 mGy). CONCLUSION The embryo/fetal doses increased with simultaneous CT scans in nuclear medicine modalities. Questioning pregnancy before scintigraphy is obligatory the first-line strategy to avoid radiation exposure risks.